I. Introduction
===============

As dental implant surgery for edentulous patients became a gold standard, bone grafts such as guided bone regeneration and sinus lift were widely operated in Korean dentist. There has been increased in the number of bone substitute products available to the dental clinician. Still the autologous bone is considered to gold standard, because of its three properties with osteoconduction, osteoinduction and osteogenesis. Osteogenesis is, the property of autogenous graft, generation of new bone from osteogenic cells within the graft. Osteoinduction is the property of the autogenous graft, allogenic graft and intrinsic bone matrix proteins such as transforming growth factor and bone morphogenetic proteins (BMP) to recruit of host stem cells. Osteoconduction is the property of a mechanical structure with biocompatibility for the migration of osteogenetic cells[@B1][@B2].

Allograft has been widely used and is an attractive alternative as it avoids donor site morbidity. It has the following advantage: (1) donor site is not needed, (2) abundant supply, and (3) little risk of transmission of infectious diseases[@B3]. The ideal alloplastic bone substitutes is biologically stable and maintain its volume with allowing cell infiltration and remodeling process[@B4]. The alloplastic bone substitutes has various osteoconductive capabilities depending on the manufacturing methods, crystal structure, size of pores, mechanical properties, composition and absorption rate[@B5].

Hydroxyapatite (HA) is the main mineralized of bone tissue and it exerts an osteoconductive ability when grafted in the defect. Synthetic calcium phosphate ceramics (β-tricalcium phosphate \[β-TCP\] and HA) could be altered to autogenous graft, allogenic graft and xenogenic graft and it was used as block, cement, pastes, powder, granules and putty type with carboxymethyl cellulose or hyaluronic acid[@B6]. In Korea, the development of implant dentistry has led to the development of many dental synthetic bone substitute in many domestic companies.

As dental implant surgery for edentulous patients became a gold standard, bone grafts such as guided bone regeneration and sinus lift were widely operated in Korean dentist. All bone substitutes used commercially in Korea are firstly evaluated by the Ministry of Health and Welfare (MOHW) for safety and efficacy of the product. They are commercialized after being priced, classified, and registration by the Health Insurance Review and Assessment Service (HIRA). The post-application management is obligatory for the manufacturer (or representative importer) to receive a certificate of Good Manufacturing Practice (GMP) by Ministry of Food and Drug Safety (MFDS).

According to Korea Food and Drug Safety (KFDS) No. 2016-156 of 'medical device manufacturing and quality control standards', after the approval of commercially use, the manufacturer or importer is required to renew the conformity certification every three years or immediately if the information of product changed[@B7]. If any information of the product changed, the certificate of conformity should be issued or reissued by the manufacturer or the importer. Therefore, the manufacturer or importer of registered in the MFDS could be important factors in terms of quality control of currently available bone substitutes.

However, it is difficult for clinicians to know whether the certification or the quality of product is properly managed. Therefore, the purpose of this study is to analyze ingredients, manufacturers, importers, current status and reference levels of dental synthetic bone listed in MOHW notification No. 2018-248.

II. Materials and Methods
=========================

Commercially available dental alloplastic bone substitute which was approved MOHW notification (No. 2018-248)[@B8] is analyzed the details of manufacturer, importer, composition, available form, Food and Drug Administration (FDA, USA) approval.

This review of literature included studies that detailed the use of bone graft substitute in dental situation, animal, *in vivo*, and *in vitro* studies. We excluded studies in the orthopedic and neurosurgery field and those not published in English or Korean. The Google Scholar, ISI Web of Knowledge, PubMed, EMBASE (1980--2019) and Cochrane Databases were searched in February 2019 using the criteria of registered or trademarked product name. The authors read the full text of the studies and classified it according to the 'level of evidence' presented by Wright et al.[@B9].([Table 1](#T1){ref-type="table"})

Human study level I evidence is a prospective, randomized, or splint-mouth study with definite results that support the use of alloplastic bone substitute in clinical condition. The case report was classified as level IV. Clinicial studies used alloplastic bone substitute as carrier of osteoinductive growth factors or as comparison of membrane efficacy have not been evaluated for osteoconductive capacity, but have been assigned to human study level IV as showing clinical stability. The animal, *in vivo*, and *in vivo* study were separately indicated. All authors reviewed each paper and independently assigned evidence levels. If there is a disagreement on the assigned level, discussion and resolution were made. All studied with human study level I, II, III, or IV were included to be citation[@B10].

III. Results
============

In December 2018, thirty-seven dental alloplastic substitutes were registered in MOHW and HIRA[@B8]. However, there were two products (BIO-C \[Cowellmedi, Busan, Korea\] and OssPol-Dental \[Genewel, Seongnam, Korea\]) that were not commercially available and one product of DualPor COLLAGEN D-INJECTION (OssGen, Daegu, Korea) that was discontinued in the market. Of the remaining 34 alloplastic substitutes, 28 products (82.4%) could be obtained information and included in this review. To approve certificate of GMP from MOHW and MFDS, the company should submit the researches for safety and efficacy of its product, as same procedure as U.S. FDA.([Table 2](#T2){ref-type="table"}) The researches, however, were not published and the authors could not include in this review. The available information regarding the delivery form, component, indications, morphology (porosity, biomechanical structure, particle size), and property are shown in [Tables 3](#T3){ref-type="table"}, [4](#T4){ref-type="table"}, [5](#T5){ref-type="table"}, [6](#T6){ref-type="table"}, [7](#T7){ref-type="table"}, [8](#T8){ref-type="table"}.

1. The products approved in FDA
-------------------------------

Seven products were approved in FDA[@B11][@B12][@B13][@B14][@B15][@B16][@B17].([Table 2](#T2){ref-type="table"}) Although TCP Dental (Kasios SAS, L\'Union, France) was not licensed for dental indication in intended use of FDA[@B17]. However, the authors included TCP Dental in this category because manufacturer did not distinguish between KASIOS TCP and (KASIOS) TCP Dental.

2. Registered in MOHW and commercially available information for product name, manufacturer, importer, and component
--------------------------------------------------------------------------------------------------------------------

The details of dental alloplastic bone substitute which was approved by MOHW notification No. 2018-248 were analyzed[@B8].([Table 3](#T3){ref-type="table"}) Among them, BIO-C and OssPol-dental were officially discontinued. CollaOss (SK Bioland, Cheonan, Korea) is registered as 60% of HA, 0.3% of bovine-derived collagen (0.3%) and 39.7% of distilled water and as block, syringe and putty types. Currently, only bock and putty type are available in the manufacturer. DualPor COLLAGEN D-PUTTY and DualPor COLLAGEN D-INJECTION is available as DualPor Collagen D-Putty and DualPor Collagen Injection, but no any information could be found.

There are seven products that do not match the manufacturer or importer registered in MOHW: (1) MBCP+ (Biometlante, Vigneux-de-Bretagne, France; sold only as MBCP and MBCP syringe type, not MBCP+), (2) Excelos Inject (Bio-Alpha, Seongnam, Korea; produced by CGbio, Seongnam, Korea), (3) Excelos (TCPGLD) (BioAlpha; produced by CGbio, sold exclusively by Excelos), (4) Boncel-Os (BioAlpha; produced by CGbio), (5) Mega-TCP (manufactured by CGbio; MegaGen, Seoul, Korea, sold as a single product without discrimination between CGM and CGL), (6) Cerasorb and Cerasorb M granule (sold only by Curasan, Kleinostheim, Germany: Cerasorb M, registered as importer) BI Trading currently available is not available), and (7) OSTEON Sinus (GENOSS, Suwon, Korea: sold as syringe type of OSTEON I, II, or III).([Table 3](#T3){ref-type="table"})

CollaOss is listed as a dental synthetic bone in the MOHW and HIRA data. Although it was represented as xenograft in the journal[@B18][@B19][@B20][@B21]; however, it was included in this review.([Table 3](#T3){ref-type="table"})

There are three products that do not match in the component registered in MOHW: (1) Cerasorb M granules (99% β-TCP not β-TCP combined with HA; Curasan), (2) FRABONE-Inject (Inobone, Cheonan, Korea: hyaluronic acid addition with HA+β-TCP), and (3) TCP Dental (99% β-TCP not 95% β-TCP combined with 5% HA).([Table 3](#T3){ref-type="table"})

As a result, out of the 33 dental bone substitutes that are currently registered in MOHW and HIRA, 28 products could be commercially available when considering the products that are different form registered information as below: Excelos (TCPGLD) and Excelos (TCPGMD, TCPGLD) are sold exclusively by Excelos, Mega-TCP (CGL) and Mega-TCP (CGM, CGL) are sold only by Mega-TCP, Cerasorb and Cerasorb M granules are sold by Cerasorb M, Cerasorb M is 99% β-TCP, FRABONE-Inject is sold by adding hyaluronic acid, CollaOss is sold in putty and block form without syringe type, DualPor COLLAGEN D-INJECTION is not produced, and TCP Dental (99% β-TCP).

3. Analysis of dental alloplastic bone substitutes according to constituents
----------------------------------------------------------------------------

The main components of dental alloplastic bone substitute are tricalcium phosphate (Ca~3~(PO~4~)~2~, β-TCP), calcium phosphate (CaP), and hydroxiapatitie (Ca~10~(PO~4~)~6~(OH)~2~, HA) which is crystalline form of CaP.([Table 4](#T4){ref-type="table"})

### 1) Dental alloplastic bone substitutes consist of hydroxyapatite

HA is an inorganic material which account for 65% of bone matrix and can be classified as dense and porous, sintered ceramic and non-ceramic, and bovine, coralline and synthetic depending on the origin. Typical characteristics are as below. (1) As large as the particle size, it remains for a long time with slow absorption. (2) The higher the porosity, the easier the penetration of new bone and the quicker absorbed. (3) The larger the crystallinity, the longer the absorption period. (4) Rigid and dense block-form products have high compressive strength but are susceptible to fracture. (5) The higher the porosity, the lower the strength[@B5].

Among the dental alloplastic bone substitutes allowed for use in Korea, there were four products that consisted of HA. OssaBase-HA (LASAK, Praha, Czech) has a retrospective study of guided bone regeneration in 2018, but it was obtained human study level IV due to a poor study design[@B22]. However, many other animal, *in vivo*, and *in vitro* studies for osteoconductivity[@B23][@B24][@B25][@B26]. No journals were found for Ovis BONE HA (DENTIS, Seoul, Korea). CollaOss consists of 90% porcine-deriven HA and 10% porcine deriven collagen. It was classified as alloplastic graft in MOHW and HIRA, on the other hands, it was introduced as xenograft in many studies[@B18][@B19][@B20][@B21]. In the manufacturer (SK Bioland), it is commercially available in plug type and putty type. In comparison with the collagenated bovine bone (Bio-Oss collagen; Geistlich Biomaterials, Woulhusen, Switzerland) into the extraction socket, it was received the human study level III because there was no difference in the efficacy[@B18]. Human study level IV was received in a clinical study to comprare the effects of membranes on peri-implant defect[@B19]. Animal studies showed osteoconductivity[@B20][@B21].([Table 4](#T4){ref-type="table"})

### 2) Dental alloplastic bone substitutes consist of tricalcium phosphate

TCP has a composition of calcium and phosphorus in ratio of 3 and 2. It was known as partially transition into HA and absorption *in vivo*, but various absorption periods of three to 24 months have been reported depending on the products. The rate of absorption varies according to the chemical structure, porosity and particle size of the material[@B5]. The general characteristics suggested by the manufacturer of TCP are as follows. (1) Use with platelet-rich plasma is effective. (2) It is absorbed at the same time as new bone graft. (3) Due to the interconnection of the pores, bone fibers are rapidly penetrated and could promote the regeneration. (4) Since the particle is rounded, there is little mechanical irrigation in surrounding tissues and little inflammatory reaction. (5) High mechanical stability prevents early collapse and inhibits undesirable macrophage activity.

Of the approved products for Korean dental alloplastic bone substitute, seven products that consist with TCP were commercialization. BoneSigma TCP (SigmaGraft, Fullerton, CA, USA) has been described as one of the *in vitro* studies[@B27], and clinically available products[@B28][@B29] but no clinical studies have been published. Excelos is registered as β-TCP etc. in MOHW and has two types of powder and injection and registered. Injection type is a mixture of biodegradable polymers such as poloxamer and hydroxypropyl methylcellulose (HPMC) to enhance injectable property, moldability and hemostasis. A clinical study comparing putty type Excelos with extraction and using as BMP carriers received a human study level IV[@B30]. Excelos has animal studies for BMP carrier[@B31][@B32] and *in vivo* study for osteoconduction[@B33]. No journals were found for Mega-TCP. Sorbone (META-BIOMED, Cheongju, Korea) was validated and received human study level II by a split-mouth study as a control of cockle-shell bone substitute in socket preservation[@B34], and used as a control material for the effect of alendronate on periodontal intra-osseous defect[@B35]. SynCera (Oscotec, Seongnam, Korea) had animal and *in vivo* study for osteoconductivity[@B36][@B37]. Cerasorb was approved by the FDA and commercially available to Cerasorb M which reduced porosity from 80% to 65%[@B11]. It was received human study level I by randomized controlled trial and systematic review that was equivalent to an autogenous graft in sinus lift[@B38][@B39]. It was received human study level III in cystic lesion, periodontal defect and cleft alveolus[@B40]. Also, as a result of histologically sufficient alveolar bone regeneration, human study level III was obtained in extraction socket[@B41]. As human study level IV, it was used with an enamel matrix derivative in the periodontal defect[@B42][@B43], peri-implant defect after immediately implantation after extraction44, every lots of animal, *in vivo*, and *in vitro* studies for osteoconduction[@B6][@B45][@B46][@B47][@B48][@B49][@B50][@B51][@B52][@B53][@B54][@B55][@B56]. TCP Dental was registered as 5% of HA and 95% of β-TCP in MOHW and HIRA. However, the manufacturer (Kasios SAS) and importer (B.IMTECH, Yongin, Korea) advertised as 99% of β-TCP. Many studies and FDA 510(k) also represented as β-TCP[@B17][@B57][@B58][@B59][@B60][@B61][@B62][@B63][@B64][@B65]. It was received human study level III by successful histologic and clinical result comparing Xenograft (BonePlus-xs; Integros, Adana, Turkey) in sinus lift[@B57]. Animal, *in vivo*, and *in vitro* studies for osteoconductivity[@B58][@B59][@B60][@B61][@B62][@B63][@B64][@B65].

### 3) Dental alloplastic bone substitutes consist with hydroxyapatite and tricalcium phosphate

The mixing ratio of HA and TCP varies from 2:8 to 7:3. It has the following characteristics. (1) It has micropore and macropore. They could induce effective tissue reaction and growth of new bone tissue. Micropores could enable ion exchange and form new contact surfaces for cell adhesion through the deposition of bone crystals. Macropores could help in angiogenesis and remodeling and growth of new bone. (2) HA acts as a mechanical support until the new bone tissue could be remolded for structural stability, and TCP could spread the adhesion surface of osteoblast by ion exchange through rapid resorption. (3) It has porosity of 70% to 90%[@B5].

Boncel-Os (CGbio) consists with 30% of HA and 70% of β-TCP. It was introduced as one of the clinically available products[@B66], and there is an animal study used as a BMP carrier[@B56]. BoneSigma BCP (SigmaGraft) consists with 60% of HA and 40% of β-TCP. *In vivo* study has been published that it inhibited osteoclast formation with plate-rich fibrin[@B67]. Dualpore Collagen D-Putty was registered as 60% of HA, 0.3% of bovine-derived collagen, and 39.7% of distilled water by the MOHW and HIRA. On the other hand, the manufacturer (OssGen) advertised the product as 60% HA and 40% β-TCP in 94.5% of biphasic CaP, and with an additional 5.5% bovine collagen but there are no reports of any evaluations of the evaluating its information provided. In MOHW and MFDS, Inobone has registrated its products as FRABONE DENTAL and FRABONE DENTLA INJECT, but they are commercially available as FRABONE and FRABONE-Inject. FRABONE (Inobone) consists with 60% of HA and 40% of β-TCP and it was received patent in USA, Germany, and Korea as mimic the harversian canal structure[@B68][@B69]. FRABONE-Inject (Inobone) is a product of hyaluronic acid addition to FRABONE, which advertised to increase moldability and absorption rate by act as soluble granules of hyaluronic acid. However, there was no related researched were found. GENESISBCP (DIO, Busan, Korea) consists with 60% of HA and 40% of β-TCP. It was received human study level II by prospective controlled clinical trial which results good outcome in periodontal defect[@B70]. In horizontal augmentation, it was showed successful result with NanoBone (HA and silica gel matrix; Artoss GmbH, Warnemünde, Germany) in case report and it obtained human study level IV[@B71]. There were many animal, *in vivo*, and *in vitro* studies for osteoconductivity[@B72][@B73][@B74][@B75][@B76][@B77]. Manufacturers have the two types of MBCP as combination of HA and β-TCP as ratio as 60:40 and 20:80, and a moldable MBCP (In\'Oss) made by mixing hydrogel to MBCP. However, represented importer (Purgo Biologics, Seongnam, Korea) only has granule or syringe type of MBCP+ which consists with 20% of HA and 80% of β-TCP. MBCP and MBCP+ were received in FDA 510(k) approved[@B12][@B16]. There were many clinical studies from MBCP which consists with 60% of HA and 40% of β-TCP[@B78][@B79][@B80][@B81][@B82][@B83][@B84]. On the other hand, MBCP+ was published only animal studies[@B85][@B86][@B87][@B88] and *in vitro* studies[@B89][@B90]. Although not introduced as MBCP+, a combination of 20% of HA and 80% of β-TCP was as same resorption and bone growth as combination of 60% of HA and 40% of β-TCP in retrospective clinical trial for extraction socket and it could be human study level IV[@B84]. Newbone (GENOSS) consists with 20% of HA and 80% of β-TCP. Although there were animal and *in vivo* studies for osteoinductivity[@B91][@B92][@B93], no clinical studies were found. Boncel-Os consists with 30% of HA and 70% of β-TCP. It was introduced as one of clinically available products[@B66] and used as BMP carrier in animal study[@B56].

OSTEON series (GENOSS) were available as vial, sinus, and lift type. OSTEON, OSTEON II, and OSTEON III were received FDA 510(k) approval[@B13][@B14][@B15]. In registration of MOHW and HIRAO, OSTEON and OSTEON Sinus were separated but OSTEON Sinus is not available product to commercially use. The manufacture (GENOSS) has classified OSTEON Sinus and OSTEON Lifting according to the size of syringe. In FDA 510(k), there also received approval as same as OSTEON, OSTEON Sinus, and OSTEON Lifting[@B13]. OSTEON consists with 70% of HA and 30% of β-TCP. In retrospective clinical study for sinus lift, OSTEON alone could result well-developed lamellar bone as same as Xenograft (Bio-Oss; Osteohealth, Shirley, NY, USA) and it could be received human study level III[@B94]. There were many animal and *in vivo* studies for osteoconductivity[@B95][@B96][@B97][@B98]. OSTEON II consists with 30% of HA and 70% of β-TCP. In retrospective clinical study for extraction socket, OSTEON II and OSTEON II Collagen were significantly more effective than collagen or native defect and the histological result was shown in animal studies[@B99]. Therefore, it could be received human study level III in extraction socket. It was received human study level IV by retrospective study as control group for sinus lift[@B100], 6 months after vertical augmentation which particulated OSTEON II was showed no significantly difference on volume change and peri-implant marginal bone loss compared with autogenous block and allogenous block bone[@B101], successful results on clinical and histologically in ridge augmentation[@B102][@B103], successful outcome on graft after implant removal[@B104], and clinically effective on periodontal defect[@B105]. Many animal and *in vivo* studies for osteoconductivity[@B95][@B96][@B97][@B106][@B107]. OSTEON III consists with 60% of HA and 40% of β-TCP. There was animal study as BMP carrier[@B108]. Although there was no OSTEON III Collagen related study, OSTEON II Collagen had animal and *in vivo* studies for osteoconductivity[@B109][@B110]. Ovis BONE BCP (DENTIS) consists with 20% of HA and 80% of β-TCP. No journals were found for Ovis BONE BCP. Q-Oss+ (OSSTEM IMPLANT, Seoul, Korea) consists with 20% of HA and 80% of β-TCP. It was received human study level IV by the clinical study on peri-implant defect[@B111]. There were *in vivo* study for osteoconductivity[@B112] TOPGEN-S (Toplan, Seoul, Korea) consists 20% of HA and 80% of β-TCP and there could not be found for journals for TOPGEN-S.

### 4) Dental alloplastic bone substitutes consist with CaP (composition not confirmed)

INNO-CaP (Cowellmedi) was advertised that consists CaP, however, the composition was not cleary known and no relevant research were found.

IV. Discussion
==============

Commercially available dental alloplastic bone substitute which was approved MOHW notification No. 2018-248 were broadly divided into 4 groups as C group (bone union and fixation group), L group (general materials), T group (human tissue), and non-insurance group. In the subcategory, there were C0 group (bone substitutes: xenograft, alloplastic graft), L7 group (dental material: dental xenograft, dental alloplastic graft), TB group (bone, demineralized bone matrix, bone block, bone chip, bone powder), non-insurance group (treatment material, human-derived bone, bone substitute containing bone morphogenetic protein \[rhBMP-2\])[@B8]. Among them, dental alloplastic bone substitutes in L7 of L group were included in this study.

The post-application management is obligatory for the manufacturer (or representative importer) to receive a certification of GMP by MFDS. According to FKDS No. 2016-156 of 'medical device manufacturing and quality control standards', the certification of GMP of human tissue or functional replacement product should be renewed every three years in article 9. According to article 10 of KFDS No. 2016-156, the certification of GMP should be reissued when any information for the products changed (change of the name of the importer or manufacturer, change of location of the importer or manufacturer). In article 12 and 15, the quality control examination agency reports periodic on the compatibility of medical device to director of KFDA[@B7]. Therefore, the manufacturer or importer of registered in the MFDS could be important factors in terms of quality control of currently available bone substitutes.

However, nineteen products (51.4%) were different information among the 37 products registered in MOHW. Four products (10.8%) were different registered ingredients from journal or advertisement including DualPor COLLAGEN D-PUTTY (OssGen), Cerasorb M granules, FRABONE-Inject, and TCP Dental. Nine products (24.3%) were differ in product name or not available including CollaOss (Syringe), Mega-TCP (CGL), Cerasorb, Cerasorb M granules, BIO-C, Excelos (TCPGMD, TCPGLD), MBCP Plus (Biometlante), OssPol DENTAL, and OSTEON Sinus. Especially, CollaOss (Block) and CollaOss (Putty) were registered as dental alloplastic bone substitute in MOHW but they were introduced as xenograft in advertisement and journals. Five products (13.5%) had different manufacturer or importer including Excelos Inject (CGbio), Excelos (TCPGLD), Excelos (TCPGMD, TCPGLD), Mega-TCP (CGM, CGL), Boncel-Os.

For a successful clinical outcome, it cannot be overemphasized that the quality of the materials or medical device should be constant and strictly controlled. Unfortunately, it is hard to identify the certification of GMP or to verify the quality in every clinical situation. Therefore, it is necessary to leave certificate to the government agency or the company which is responsible for the product. In addition the related dental institute or academy should to consider the security on quality of the product.

Implant dentistry has become a common treatment in Korea, many studies and development have been made on implant and bone graft materials. Among dental alloplastic bone substitutes which were registered in MOHW, twenty-nine (78.4%) products were domestically produced, of which three out of seven approved by FDA were made in Korea[@B11][@B12][@B13][@B14][@B15][@B16][@B17]. However, there are only ten products (27.0%) have been published with clinical study, of which six are Korean products. In the view of reference, the reference level could not be as directly same as the efficiency of the product, but it could be the basis of product selection for the clinician since minimal safety and efficiency can be regarded as verified. Reference level I received Cerasorb M (β-TCP 99%) as a sinus lift[@B38][@B39]. Reference level II received Sorbone (β-TCP 100%) in extraction socket and periodontal defect[@B34][@B35], GENESIS-BCP (β-TCP 40% and HA 60%) in periodontal defect[@B70]. Reference level III received Cerasorb M (β-TCP 99%) in cystic cavity, periodontal defect, cleft defect and extraction socket[@B40][@B41], CollaOss (HA 90% and collagen 10%) in extraction socket[@B18], OSTEON (β-TCP 30% and HA 70%) in sinus lift[@B94], OSTEON II (β-TCP 70% and HA 30%) in sinus lift[@B99], TCP Dental (β-TCP 99.9%) in sinus lift[@B57]. Reference level IV is insufficient to verify the efficiency, could be seen as a step that clinically confirms safety. Cerasorb M was in peri-implant and periodontal defect[@B42][@B43][@B44], CollaOss was in peri-implant defect[@B19], OssaBase-HA (HA 100%) was in guided bone regeneration[@B22], Excelos (β-TCP 100%) was in extraction socket[@B30], MBCP+ (β-TCP 80% and HA 20%) was in extraction socket[@B84], GENESISBCP was in ridge augmentation[@B71], OSTEON II was in sinus lift[@B100], ridge augmentation[@B101][@B102][@B103], periodontal defect[@B105] achieved for reference level IV. In addition, there were many animal, *in vivo*, and *in vitro* studies for osteoconductivity or role as carrier of osteoinductive growth factors or control material. In order to obtain MOHW and MFDS approval for commercial use in Korea, a data based on research or experiments should be required, but these data could not be included in this study because they were not publicly available. Because dental bone graft surgery has been performed in various environments such as sinus lift, ridge augmentation, cystic lesion, periodontal defect, peri-implant defect, extraction socket, it could be difficult to obtain high reference level in all dental bone grafting fields. However, it is nevertheless necessary to demonstrate the clinical level of Korean dental operation and the development level of bone graft substitutes.

In conclusion, there is not enough information about the effectiveness and safety of currently available alloplastic bone substitute in dental performance. Further clinical trials including well designed RCTs are necessary to evaluation the clinical efficacy of dental alloplastic bone substitutes in Korea. It should be aware of the limited information and developed the clinical evidences and regulations for clinicians.
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###### Level of evidence for research questions[@B9]

![](jkaoms-45-51-i001)

  Type                                             Level                                                                                        Description
  ------------------------------------------------ -------------------------------------------------------------------------------------------- -----------------------------------
  Published human studies                          I                                                                                            Randomized controlled trial (RCT)
  Split-mouth study                                                                                                                             
  II                                               Prospective cohort^1^                                                                        
  Systematic review with level II studies                                                                                                       
  Poor-quality RCT (e.g., \<80% follow-up)                                                                                                      
  III                                              Case-control study^2^                                                                        
  Retrospective cohort study^3^                                                                                                                 
  Systematic review with under level III studies                                                                                                
  IV                                               Case series or case report no/or historical, control group and poor designed human studies   
  Animal studies                                                                                                                                
  *In vivo* studies (cell culture)                                                                                                              
  *In vitro* studies                                                                                                                            

^1^Patients were compared with a control group of patients treated at the same time and same institution.

^2^Patients with a particular outcome ('cases') were compared with those who did not have the outcome ('controls').

^3^The study was initiated after treatment was performed.

###### Dental bone graft substitutes which Food and Drug Administration (FDA) 510(k) approved

![](jkaoms-45-51-i002)

  Product name                                                                                                                                         Approved date (mo/day/yr)   Indications with FDA 510(k) approved
  ---------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------- ----------------------------------------------------------------
  Cerasorb M granules                                                                                                                                  7/22/2005                   Alveolar augmentation
  Filling of defects after root resection, apicoectomy, and cystectomy                                                                                                             
  Filling of extraction sockets                                                                                                                                                    
  Elevation of the maxillary sinus floor                                                                                                                                           
  Filling of periodontal/perio-implant defects for GTR and GBR                                                                                                                     
  MBCP                                                                                                                                                 12/11/2003                  Bone void filler for bony voids or gaps of the skeletal system
  Used with autograft as a bone graft extender                                                                                                                                     
  Osseous defects and/or from traumatic injury to the bone.                                                                                                                        
  Without initial mechanical properties. Therefore, rigid fixation techniques may often be recommended. Gradually resorbs and is replaced with bone.                               
  MBCP Plus, MBCP+                                                                                                                                     7/30/2007                   Periodontal/infrabony defects
  Ridge augmentation                                                                                                                                                               
  Extraction site (for implant)                                                                                                                                                    
  Sinus graft and cyst defect                                                                                                                                                      
  OSTEON                                                                                                                                               7/8/2010                    Periodontal/infrabony defects
  Ridge augmentation                                                                                                                                                               
  Extraction site (for implant)                                                                                                                                                    
  Sinus lifts                                                                                                                                                                      
  Cystic cavities                                                                                                                                                                  
  OSTEON II                                                                                                                                            12/26/2011                  Periodontal/infrabony defects
  Ridge augmentation                                                                                                                                                               
  Extraction site (implant preparation/placement)                                                                                                                                  
  Sinus lifts                                                                                                                                                                      
  Cystic cavities                                                                                                                                                                  
  OSTEON III                                                                                                                                           9/14/2016                   Periodontal/infrabony defects
  Ridge augmentation                                                                                                                                                               
  Extraction site (implant preparation/placement)                                                                                                                                  
  Sinus lifts                                                                                                                                                                      
  Cystic cavities                                                                                                                                                                  
  TCP Dental                                                                                                                                           11/10/2004                  Cystic cavities
  Packed into bony voids or gaps of the skeletal system (such as the extremities, spine and the pelvis).                                                                           
  Osseous defects and/or from traumatic injury to the bone.                                                                                                                        
  Resorbs and is replaced with bone during the healing process.                                                                                                                    
  -Approved for KASIOS TCP not (KASIOS) TCP Dental                                                                                                                                 

(GTR: guided tissue regeneration, GBR: guided bone regeneration)

###### Dental bone graft substitutes with manufactures, importer, components and inconsistency with registered in Korean Ministry of Health and Welfare and Korean Health Insurance Review and Assessment Service

![](jkaoms-45-51-i003)

  Product name                            Manufacturer     Nationality   Importer name       Registered components                                           Remarks
  --------------------------------------- ---------------- ------------- ------------------- --------------------------------------------------------------- -------------------------------------------------------------------------
  OSSABASE-HA                             LASAK            Czech         Mono Dent           HA                                                              OSSABASE-HA → OssaBase-HA
  OVIS BONE HA                            DENTIS           Korea         DENTIS              HA                                                              OVIS BONE HA → Ovis BONE HA
  COLLAOSS (BLOCK), OOSSBONE COLLAGEN     SK Bioland       Korea         SK Bioland          HA (90%±5%)+collagen (10%±5%)                                   COLLAOSS (BLOCK), OSSBONE COLLAGEN → CollaOss (BLOCK), OssBone collagen
  COLLAOSS (PUTTY)                        SK Bioland       Korea         SK Bioland          HA (90%±5%)+collagen (10%±5%)                                   COLLAOSS (PUTTY) → CollaOss (PUTTY)
  Role out xenograft                                                                                                                                         
  COLLAOSS (SYRINGE)                      SK Bioland       Korea         SK Bioland          HA (90%±5%)+collagen (10%±5%)                                   COLLAOSS (SYRINGE) → CollaOss
  Only block and putty type of CollaOss                                                                                                                      
  DUALPOR COLLAGEN D-PUTTY                OssGen           Korea         OssGen              HA (60%)+bovine atelo collagen (0.3%)+distilled water (39.7%)   DUALPOR COLLAGEN D-PUTTY → DualPor Collagen D-Putty
  HA (60%)+β-TCP (40%)+bovine collagen                                                                                                                       
  DUALPOR COLLAGEN D-INJECTION            OssGen           Korea         OssGen              HA (60%)+bovine atelo collagen (0.3%)+distilled water (39.7%)   DUALPOR COLLAGEN D-INJECTION → DualPor Collagen Injection
  NA                                                                                                                                                         
  BONESIGMA TCP                           SigmaGraft       USA           KodentTMS           β-TCP 100%                                                      BONESIGMA TCP → BoneSigma TCP
  EXCELOS INJECT                          BioAlpha         Korea         BioAlpha            β-TCP etc.                                                      EXCELOS INJECT → Excelos INJECT
  BioAlpha → CGbio                                                                                                                                           
  EXCELOS (TCPGLD)                        BioAlpha         Korea         BioAlpha            β-TCP 100%                                                      EXCELOS (TCPGLD) → Excelos (TCPGLD)
  BioAlpha → CGbio                                                                                                                                           
  EXCELOS (TCPGMD, TCPGLD)                BioAlpha         Korea         BioAlpha            β-TCP 100%                                                      EXCELOS (TCPGMD, TCPGLD) → Excelos (TCPGMD, TCPGLD)
  BioAlpha → CGbio                                                                                                                                           
  MEGA-TCP (CGL)                          CGbio            Korea         CGbio               β-TCP 100%                                                      MEGA-TCP (CGL) → Mega-TCP
  CG bio → MegaGen                                                                                                                                           
  Mega-TCP (CGM, CGL)                     CGbio            Korea         CGbio               β-TCP 100%                                                      MEGA-TCP (CGM, CGL) → Mega-TCP
  NA                                                                                                                                                         
  SORBONE                                 META-BIOMED      Korea         META-BIOMED         β-TCP 100%                                                      SORBONE → Sorbone
  SYNCERA                                 Oscotec          Korea         Oscotec             β-TCP                                                           SYNCERA → Syncera
  CERASORB                                Curasan          Germany       B.ITRADING          β-TCP                                                           Cerasorb → Cerasorb M
  BIO-C                                   Cowellmedi       Korea         Cowellmedi          β-TCP+HA                                                        NA
  BONCELOS                                BioAlpha         Korea         BioAlpha            β-TCP+HA                                                        BONCELOS → Boncel-Os
  BioAlpha → CGbio                                                                                                                                           
  BONESIGMA BCP                           SigmaGraft       USA           KODENT TMS          β-TCP (40%)+HA (60%)                                            BONESIGMA BCP → BoneSigma BCP
  CERASORB M GRANULES                     Curasan          Germany       Mono Dent           β-TCP+HA                                                        CERASORB M GRANULES → Cerasorb M
  HA+β-TCP → 99% β-TCP                                                                                                                                       
  FRABONE DENTAL                          Inobone          Korea         Inobone             β-TCP (40%±5%)+HA (60%±5%)                                      FRABONE DENTAL → FRABONE
  FRABONE DENTAL INJECT                   Inobone          Korea         Inobone             β-TCP+HA                                                        FRABONE DENTAL INJECT → FRABONE-Inject
  Hyaluronic acid addition                                                                                                                                   
  GENESIS-BCP                             DIO              Korea         DIO                 β-TCP (40%)+HA (60%)                                            N/S
  MBCP                                    Biometlante      France        Purgo Biologics     β-TCP+HA                                                        N/S
  MBCP PLUS                               Biometlante      France        Purgo Biologics     β-TCP+HA                                                        MBCP PLUS → MBCP or/with syringe type
  NEW BONE                                GENOSS           Korea         GENOSS              β-TCP+HA                                                        NEW BONE → Newbone
  OSSPOL DENTAL                           Genewel          Korea         Genewel             β-TCP (40%)+HA (60%)                                            OSSPOL DENTAL → OssPol
  NA                                                                                                                                                         
  OSTEON                                  GENOSS           Korea         GENOSS              HA (β-TCP)                                                      N/S
  OSTEON II                               GENOSS           Korea         GENOSS              β-TCP+HA                                                        N/S
  OSTEON III                              GENOSS           Korea         GENOSS              β-TCP+HA                                                        N/S
  OSTEON III COLLAGEN                     GENOSS           Korea         GENOSS              β-TCP+porcine collagen (95%)                                    N/S
  OSTEON SINUS                            GENOSS           Korea         GENOSS HA (β-TCP)                                                                   Only syringe type of OSTEON I, II, and III
  OVIS BONE HA                            DENTIS           Korea         DENTIS              β-TCP+HA                                                        OVIS BONE HA → Ovis BONE HA
  TCP Dental                              Kasios SAS       France        B.IMTECH            β-TCP (95%)+HA (5%)                                             β-TCP (95%)+HA (5%) → β-TCP (99.9%)
  Q-OSS+                                  OSSTEM IMPLANT   Korea         OSSTEM IMPLANT      β-TCP (80%±5%)+ HA (20%±5%)                                     N/S
  TOPGEN-S                                Toplan           Korea         Toplan              β-TCP (80%±5%)+ HA (20%±5%)                                     N/S
  INNO CAP                                Cowellmedi       Korea         Cowellmedi          Calcium phosphate (100%)                                        INNO CAP → INNO-CaP

(HA: hydroxyapatite, β-TCP: β-tricalcium phosphate, NA: not available, N/S: nothing special)

###### Commercially available dental alloplastic bone substitutes according to components

![](jkaoms-45-51-i004)

  Commercially available dental alloplastic bone substitutes   Total (n=28)
  ------------------------------------------------------------ --------------
  Hydroxyapatite (HA)                                          4
  β-Tricalcium phosphate (β-TCP)                               8
  β-TCP+HA                                                     15
  Calcium phosphate (CaP: composition not confirmed)           1

###### Dental bone graft substitutes which was consisted with hydroxyapatite (HA)

![](jkaoms-45-51-i005)

  Product name                                                                     Delivery                                              Component                                                     Indication                               Morphology                       Property                                         Level of evidence
  -------------------------------------------------------------------------------- ----------------------------------------------------- ------------------------------------------------------------- ---------------------------------------- -------------------------------- ------------------------------------------------ ---------------------------------------------------------------------------
  OssaBase-HA                                                                      Granule                                               HA:CaP (1.65), Ca~10~(Po~4~)~6~(OH)~2~                        Remodeling of the alveolar ridge         Macro-nano bone like structure   Volume maintenance                               Human study level (IV: GBR[@B22])
  Treatment of periodontal defects                                                 83% interconnected porosity                           Low substitution rate                                         Animal, *in vivo* , *in vitro* studies                                                                                     
  Treatment of bone defects around dental implants                                 Narrow size ranges of available granules              No risk of immunological reactions or pathogen transmission                                                                                                                              
  Sinus lift                                                                       Enough space for bone ingrowth over large distances                                                                                                                                                                                            
  Filling of bone defects after surgical extractions to prevent alveolar atrophy                                                                                                                                                                                                                                                  
  Filling of bone defects after extirpation of cysts                                                                                                                                                                                                                                                                              
  Ovis BONE HA                                                                     Granule                                               100% HA                                                       Periodontal bone defect                  Well-formed macro/micro porous   Osteoconductivity                                NA
  Intrabony defect                                                                 Porosity                                              Biocompatibility                                                                                                                                                                         
  Extraction site                                                                                                                        Non toxicity                                                                                                                                                                             
  Ridge augmentation                                                                                                                     Non inflammatory nature                                                                                                                                                                  
  Sinus lift                                                                                                                             Easy manipulation                                                                                                                                                                        
  Cystic cavity                                                                                                                                                                                                                                                                                                                   
  CollaOss (Block), Ossbone Collagen                                               Plug                                                  HA 90%±5%+ collagen 10%±5%                                    Periodontal bone defect                  Well-formed macro/micro porous   Easy manipulation and adhesion due to collagen   Human study (III: extraction socket[@B18], IV: peri-implant defect[@B19])
  Intrabony defect                                                                 Porosity                                              Slow absorption and partial remodeling                                                                                                                                                   
  CollaOss (Putty)                                                                 Granule                                               HA 90%±5%+collagen 10%±5%                                     Periodontal bone defect                  Well-formed macro/micro porous   Easy manipulation and adhesion due to collagen   Animal study
  Intrabony defect                                                                 Porosity                                              Slow absorption and partial remodeling                                                                                                                                                   

(CaP: calcium phosphate, GBR: guided bone regeneration, NA: data not available)

###### Dental bone graft substitutes which was consisted with β-tricalcium phosphate (β-TCP)

![](jkaoms-45-51-i006)

  Product name                                                Delivery                                                                                        Component                                                                      Indication                                                   Morphology                                                                                                               Property                                                Level of evidence
  ----------------------------------------------------------- ----------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------ ------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  BoneSigma TCP                                               Powder                                                                                          β-TCP 100%                                                                     Extraction socket                                            \>95% β-TCP                                                                                                              Osteoconductive                                         *In vitro* study
  Horizontal and vertical augmentation                        Interconnected macro and micro porous structure                                                 High resorption rate: rapid osseointegration and recovery in dental implants                                                                                                                                                                                                                                                 
  Peri-implant defects                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  Periodontal regeneration                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Ridge augmentation                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  Sinus floor elevation                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Excelos Inject                                              Injectable                                                                                      β-TCP 100%                                                                     Sinus lift                                                   β-TCP particle (size: 45-75 μm) with hydrogel (poloxamer, hydroxypropyl methylcellulose \[HPMC\])                        Hemostasis and injectable by poloxamer-based hydrogel   Human study level (IV: extraction socket[@B30])
  Guided bone regeneration                                    High moldability                                                                                Animal studies (for BMP carrier), *in vivo*, *in vitro* studies                                                                                                                                                                                                                                                              
  Socket preservation                                         Osteoconductive                                                                                                                                                                                                                                                                                                                                                                                                              
                                                              High resorption rate                                                                                                                                                                                                                                                                                                                                                                                                         
                                                              Space maintaining for new bone formation                                                                                                                                                                                                                                                                                                                                                                                     
  Excelos (TCPGLD)                                            Powder                                                                                          β-TCP 100%                                                                     Sinus floor elevation                                        100% β-TCP                                                                                                               Osteoconductive                                         Animal, *in vitro* studies
  Alveolar bone augmentation                                  Average 80% macro-porosity (pore size: 100-300 μm)                                              Faster absorption and biodegrade rate                                                                                                                                                                                                                                                                                        
  Extraction socket preservation                                                                                                                              Space maintaining for new bone formation                                                                                                                                                                                                                                                                                     
  MEGA-TCP (CGL)                                              Powder                                                                                          β-TCP 100%                                                                     NA                                                           Porous structure like human cancellous bone                                                                              Biocompatibility                                        NA
  \>99% interconnectivity                                     Biodegradable                                                                                                                                                                                                                                                                                                                                                                                                                
  Average 75% macro-porosity (pore size: 100-300 μm)                                                                                                                                                                                                                                                                                                                                                                                                                                       
  Sorbone                                                     Powder                                                                                          β-TCP 100%                                                                     Extraction socket                                            Average 55%-60% macro-porosity                                                                                           Osteoconductive                                         Human study (level II, socket preservation[@B34] and periodontal defect[@B35])
  Cystic cavities                                             High resorption rate                                                                                                                                                                                                                                                                                                                                                                                                         
  Periodontal defects                                         Biocompatibility                                                                                                                                                                                                                                                                                                                                                                                                             
  Intrabony defects                                           Easy handling                                                                                                                                                                                                                                                                                                                                                                                                                
  Ridge augmentation                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  Sinus floor elevation                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  SynCera                                                     Powder                                                                                          β-TCP 100%                                                                     NA                                                           Macro- and micro-porosity                                                                                                Osteoinduction                                          Animal, *in vivo*, *in vitro* studies
                                                              \>70% new bone formation                                                                                                                                                                                                                                                                                                                                                                                                     
  Cerasorb M                                                  Powder                                                                                          β-TCP 99%                                                                      Augmentation or reconstructive treatment of alveolar ridge   Micro-meso-macro pore (pore size 5-500 μm) about 65% porosity with full range of pore size and interconnected porosity   99% resorption                                          Human study level (I: sinus[@B38][@B39], III: cystic lesion, periodontal defect, cleft alveolus[@B40], extraction socket preservation[@B41], IV: peri-implant defect[@B44], periodontal defect with enamel matrix derivative [@B42][@B43])
  Infrabony periodontal defects                               Optimal microencironment for osteoblast adhesion proliferation and Subsequent bone remodeling   Animal, *in vivo*, *in vitro* studies                                                                                                                                                                                                                                                                                        
  Defects after root resection, apicoectomy, and cystectomy                                                                                                                                                                                                                                                                                                                                                                                                                                
  Extraction socket                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Sinus lift                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Guided tissue regeneration                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Guided bone regeneration                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Peri-implant defect                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  TCP Dental                                                  Granule                                                                                         β-TCP 99%                                                                      Sinus graft                                                  Interconnected macro-porosity                                                                                            Osteoconductive                                         Human study (III: sinus graft[@B57])
  Bone loss correction                                        \>90% porosity (pore size: 0.2-0.5 mm)                                                          Early resobable and angiogenesis                                               Animal, in vivo , in vitro for osteoconduction                                                                                                                                                                                                
  Filling alveoli                                             Particle size: 0.15-2.0 mm                                                                                                                                                                                                                                                                                                                                                                                                   
  Periodontology                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

(BMP: bone morphogenetic proteins, NA: data not available)

###### Dental bone graft substitutes which was composed with hydroxyapatite (HA) and β-tricalcium phosphate (β-TCP)

![](jkaoms-45-51-i007)

  Product name                                                Delivery                                                                                                                     Component                                                              Indication                                          Morphology                                                                                                                                       Property                                                        Level of evidence
  ----------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------- --------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Boncel-Os                                                   Granule                                                                                                                      β-TCP (70%)+HA (30%)                                                   Ridge augmentation                                  High porosity                                                                                                                                    High biocompatibility                                           Animal study
  Extraction sockets                                          Interconnected porous structure                                                                                              Osteoconduction                                                                                                                                                                                                                                                                                                                             
  Periodontal defect                                                                                                                                                                       Excellent wettability                                                                                                                                                                                                                                                                                                                       
  Sinus lift                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  BoneSigma BCP                                               Granule                                                                                                                      β-TCP (40%)+HA (60%)                                                   Ridge augmentation                                  Micro- and macro-porosity                                                                                                                        Osteoconductive properties                                      *In vivo* study
  Extraction sockets                                                                                                                                                                       Long-term volume stability                                                                                                                                                                                                                                                                                                                  
  Cystic cavities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Sinus floor elevation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  Periodontal defects                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Peri-implant defects                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  DualPor COLLAGEN D-PUTTY                                    Block                                                                                                                        β-TCP (40%)+HA (60%)+bovine collagen (5.5%)                            NA                                                  Trabecular like structure                                                                                                                        Biocompatibility                                                NA
  Interconntected macro- and micro-porosity 80% of porosity   Bioabsorbable                                                                                                                                                                                                                                                                                                                                                                                                                                                            
                                                              Easy handling and moldable                                                                                                                                                                                                                                                                                                                                                                                                                                               
                                                              Hemostasis and anti-adhesion effect                                                                                                                                                                                                                                                                                                                                                                                                                                      
  FRABONE                                                     Granule                                                                                                                      β-TCP (40%)+HA (60%)                                                   NA                                                  Haversian canal like structure (international patent: PCT/KR2011/005509-USA and Germany), 150-300 μm macropore                                   Biocompatibility                                                
  Average 8.1 μm micropore0.7 mm size of porous particles     Bioactive                                                                                                                                                                                                                                                                                                                                                                                                                                                                
                                                              Osteoconductivity                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                              Osteoinductivity                                                                                                                                                                                                                                                                                                                                                                                                                                                         
                                                              Mechanical strength                                                                                                                                                                                                                                                                                                                                                                                                                                                      
                                                              Structural feature reserves stable room and filled up with vessels and new bone material, resulting in faster regeneration                                                                                                                                                                                                                                                                                                                                               
  FRABONE-Inject                                              Injection                                                                                                                    β-TCP (40%±5%)+HA (60%±5%)+coated with hyaluronic acid                 NA                                                  Haversian canal like structure (international patent: PCT/ KR2011/005509-USA and Germany),100-300 μm micropore 0.7 mm size of porous particles   Highly biocompatible and bioresorbable due to hyaluronic acid   NA
                                                              Osteoconductivity                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                              Osteoinductivity                                                                                                                                                                                                                                                                                                                                                                                                                                                         
                                                              High mechanical strength                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                              Structural feature                                                                                                                                                                                                                                                                                                                                                                                                                                                       
                                                              Moldability                                                                                                                                                                                                                                                                                                                                                                                                                                                              
                                                              Injectability                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  GENESIS-BCP                                                 Granule                                                                                                                      β-TCP (40%)+HA (60%)                                                   NA                                                  70% of complete interconntected porosity 75% macropore (300-700 μm)                                                                              High mechanical strength                                        Human studies (level II: periodontal defect[@B70], level IV: horizontal augmentation[@B71])
  25% micropore (\<10 μm)                                     Highly biocompatible                                                                                                         Animal, *in vivo*, *in vitro* studies for osteoconduction                                                                                                                                                                                                                                                                                   
  MBCP Plus                                                   Granule                                                                                                                      β-TCP (80%)+HA (20%)                                                   Sinus lift augmentation                             70% porosity with 35% microporosity                                                                                                              Permeable                                                       Human study (level IV: extraction socket[@B84])
  Ridge augmentation                                          1/3 micropores (\<10 μm)                                                                                                     Resorbable                                                             Animal, *in vivo*, *in vitro* for osteoconduction                                                                                                                                                                                                                    
  Alveolar regeneration                                       2/3 macropores (300-600 μm)                                                                                                  Hydrophilic                                                                                                                                                                                                                                                                                                                                 
  Alveolar regeneration                                                                                                                                                                    Bioactive                                                                                                                                                                                                                                                                                                                                   
  Intra-osseous pockets                                                                                                                                                                    Osteoconductive                                                                                                                                                                                                                                                                                                                             
                                                                                                                                                                                           Regeneration                                                                                                                                                                                                                                                                                                                                
  NEW BONE                                                    Granule                                                                                                                      β-TCP (80%)+HA (20%)                                                   Ridge augmentation                                  80% porosity (pore size: 200-400 μm)                                                                                                             Osteoconductive synthetic bone graft                            Animal study
  Extraction site and osteotomy                               0.2-2.0 mm size of porous particles                                                                                          Highly resorbable due to 80% β-TCP                                                                                                                                                                                                                                                                                                          
  Cystic cavities                                                                                                                                                                          Easy manipulation                                                                                                                                                                                                                                                                                                                           
  Sinus lift                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Periodontal defect                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  OSTEON                                                      Granule/syringe                                                                                                              β-TCP (30%)+HA (70%)                                                   Periodontal/infrabony defects                       HA coated with β-TCP                                                                                                                             Osteoconductive                                                 Human study (level III: sinus lift[@B94])
  Ridge augmentation                                          Interconnected porous structure similar to that of human cancellous bone                                                     Animal, in vivo, *in vitro* for osteoconduction                                                                                                                                                                                                                                                                                             
  Extraction site (implant preparation/placement)             77% porosity (pore size: 300-500                                                                                                                                                                                                                                                                                                                                                                                                                                         
  Sinus lift                                                  Irregular shaped particles of size                                                                                                                                                                                                                                                                                                                                                                                                                                       
  Cystic cavities                                             Particle size (granule): 0.3-2.0 mm                                                                                                                                                                                                                                                                                                                                                                                                                                      
                                                              Particle size (sinus, syringe): 0.5-2.0 mm                                                                                                                                                                                                                                                                                                                                                                                                                               
                                                              Particle size (lifting, syringe): 0.3-1.0 mm                                                                                                                                                                                                                                                                                                                                                                                                                             
  OSTEON II                                                   Granule/syringe                                                                                                              β-TCP (70%)+HA (30%)                                                   Periodontal/infrabony defects                       Interconnected porous structure similar to that of human cancellous bone                                                                         Highly resorbable due to higher β-TCP content                   Human study (level III: extraction socket[@B99], level IV: sinus lift[@B100], vertical ridge augmentation[@B101], ridge augmentation[@B102][@B103], periodontal defect[@B105])
  Ridge augmentation                                          \>70% porosity (pore size: 250 μm)                                                                                           Easy manipulation                                                      Animal, *in vivo* for osteoconduction                                                                                                                                                                                                                                
  Extraction site (implant preparation/placement)             Irregular shaped particles of size                                                                                           Excellent wettability                                                                                                                                                                                                                                                                                                                       
  Sinus lift                                                  Particle size (granule): 0.2-2.0 mm                                                                                          Osteoconductive                                                                                                                                                                                                                                                                                                                             
  Cystic cavities                                             Particle size (sinus, syringe): 0.5-2.0 mm                                                                                                                                                                                                                                                                                                                                                                                                                               
                                                              Particle size (lifting, syringe): 0.2-1.0 mm                                                                                                                                                                                                                                                                                                                                                                                                                             
  OSTEON III                                                  Granule/syringe                                                                                                              β-TCP (40%)+HA (60%)                                                   Periodontal/infrabony defects                       Interconnected macro and micro porous structure                                                                                                  Biocompatible                                                   Animal study (BMP carries)
  Ridge augmentation                                          \<80% porosity                                                                                                               Osteoconductive                                                                                                                                                                                                                                                                                                                             
  Extraction site (implant preparation/placement)             Particle size (granule): 0.2-2.0 mm                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Sinus lift                                                  Particle size (sinus, syringe): 0.5-2.0 mm                                                                                                                                                                                                                                                                                                                                                                                                                               
  Cystic cavities                                             Particle size (lifting, syringe): 0.2-1.0 mm                                                                                                                                                                                                                                                                                                                                                                                                                             
                                                              \>70% crystallinity                                                                                                                                                                                                                                                                                                                                                                                                                                                      
                                                              CaP=1.59                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  OSTEON III Collagen                                         Cylinder                                                                                                                     β-TCP (40%)+HA (60%)+type I collagen (\>95% porcine tendon collagen)   Alveolar bone defect                                Particle size: 0.2-1.0 mm                                                                                                                        Easy manipulation                                               NA
  Excellent wettability                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  Ovis BONE BCP                                               Granule                                                                                                                      β-TCP (80%)+HA (20%)                                                   Periodontal bone defect                             70% porosity (pore size: 20 μm)                                                                                                                  Osteoconductive                                                 NA
  Intrabony defect                                            Particle size: 0.3-2.0 mm                                                                                                    Excellent wettability                                                                                                                                                                                                                                                                                                                       
  Extraction site                                                                                                                                                                          Easy manipulation                                                                                                                                                                                                                                                                                                                           
  Ridge augmentation                                                                                                                                                                       Biocompatibility and great bioactivity                                                                                                                                                                                                                                                                                                      
  Sinus lift                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Cystic cavitiy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  Q-OSS+                                                      Granule                                                                                                                      β-TCP (80%)+HA (20%)                                                   NA                                                  Porous structure                                                                                                                                 Excellent hydrophilicity                                        Cell culture
  Osteoconductive                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Biocompatibile                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  Bioasorbable                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  Rapid osteogenesis rate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  TOPGEN-S                                                    Granule                                                                                                                      β-TCP (80%)+HA (20%)                                                   NA                                                  Interconnected macro and microporous                                                                                                             Excellent hydrophilicity                                        NA
  Particle size: 1.0-2.0 mm                                   Osteoconductive                                                                                                                                                                                                                                                                                                                                                                                                                                                          

(NA: data not available, CaP: calcium phosphate, BMP: bone morphogenetic proteins)

###### Dental bone graft substitutes which was consisted with calcium phosphate

![](jkaoms-45-51-i008)

  Product name               Delivery            Component                    Indication   Morphology                     Property                                                                    Level of evidence
  -------------------------- ------------------- ---------------------------- ------------ ------------------------------ --------------------------------------------------------------------------- -------------------
  INNO-CaP                   Granule             Calc*i*um phosphate (100%)   Sinus lift   0.41-1.4 mm of particle size   Completely resorpted and progressively replaced by normal-structured bone   NA
  Guided bone regeneration   Biocompatibility                                                                                                                                                         
                             Osteoconductivity                                                                                                                                                        
                             Safety                                                                                                                                                                   

(NA: data not available)
